Study preserves hopes for Roche's Tecentriq in lung cancer
ZURICH (Reuters) - Swiss drugmaker Roche's hopes of having the first immunotherapy cocktail to be approved as an initial treatment for an aggressive form of lung cancer remained intact on Monday after a trial showed positive survival data.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Health | Immunotherapy | Lung Cancer | Study | Switzerland Health